Halozyme Therapeutics, Inc.
HALO
$38.57
$0.110.29%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 829.25M | 780.71M | 773.65M | 704.98M | 660.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 829.25M | 780.71M | 773.65M | 704.98M | 660.12M |
| Cost of Revenue | 268.72M | 259.78M | 251.66M | 231.29M | 205.91M |
| Gross Profit | 560.53M | 520.93M | 522.00M | 473.70M | 454.21M |
| SG&A Expenses | 149.18M | 127.42M | 126.62M | 145.15M | 121.63M |
| Depreciation & Amortization | 68.77M | 58.06M | 67.42M | 60.98M | 43.15M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 486.68M | 445.26M | 445.69M | 437.42M | 370.69M |
| Operating Income | 342.57M | 335.45M | 327.96M | 267.56M | 289.43M |
| Income Before Tax | 348.33M | 317.95M | 289.89M | 226.75M | 248.92M |
| Income Tax Expenses | 66.74M | 64.04M | 56.19M | 45.11M | 46.79M |
| Earnings from Continuing Operations | 281.59 | 253.91 | 233.71 | 181.64 | 202.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 281.59M | 253.91M | 233.71M | 181.64M | 202.13M |
| EBIT | 342.57M | 335.45M | 327.96M | 267.56M | 289.43M |
| EBITDA | 419.43M | 398.73M | 400.56M | 332.88M | 336.07M |
| EPS Basic | 2.14 | 1.91 | 1.74 | 1.34 | 1.48 |
| Normalized Basic EPS | 1.60 | 1.53 | 1.45 | 1.15 | 1.25 |
| EPS Diluted | 2.11 | 1.88 | 1.71 | 1.31 | 1.45 |
| Normalized Diluted EPS | 1.58 | 1.50 | 1.42 | 1.12 | 1.22 |
| Average Basic Shares Outstanding | 527.78M | 534.01M | 538.57M | 544.78M | 547.41M |
| Average Diluted Shares Outstanding | 536.56M | 544.13M | 549.43M | 558.10M | 561.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
